Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Interim report January – September 2024
The Group in summary 01/07/24 01/07/23 01/01/24 01/01/23 Full year -30/09/24 -30/09/23 -30/09/24 -30/09/23 2023 Net sales 2 531 3 024 7 660 6 389 8 015 Operating result...Invitation to conference call and audiocast in connection with the interim report
Stockholm, November 11, 2024 – Intervacc AB (publ) will publish its interim report for the period January to September 2024 on Thursday 14 November 2024, at 08:30 CET. CEO Jonas Sohlman and CFO Jan Persson will present the report at a conference call and audiocast...Out-of-stock situation regarding Strangvac in Sweden resolved
Stockholm, October 21, 2024 – Intervacc AB (publ) announces that the shortage situation for the equine strangles vaccine Strangvac® in Sweden has been resolved and the vaccine is again in stock for distribution and sales. As previously announced, the shortage...Intervacc identifies a potential short out-of-stock situation regarding Strangvac
Stockholm, September 20, 2024 – Intervacc AB (publ) predicts that the vaccine Strangvac®, which is approved for sale in Europe and the UK, may be out-of-stock for a short period from the 1st October 2024. The doses of vaccine that are currently available for...Extended Patent Protection for Strangvac approved in the United Kingdom
Stockholm, September 20, 2024 – Intervacc AB (publ) announces that the application for supplementary protection for Strangvac®, an innovative vaccine against strangles, has now been approved in the United Kingdom. This supplementary protection extends the existing...Nyhetstjänster
